Recent Updates
Recently added Catalysts

R209130

Phase 2

Schizophrenia | Small molecule | Psychiatry |Johnson & Johnson|Last Updated: Aug 28, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment180
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00063297Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of SchizophreniaPHASE2 COMPLETED 180May 1, 2003Oct 1, 2003Aug 28, 200929 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
R209130DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexALL
Healthy VolunteersNo
Study Sites29

Inclusion: * Adults aged 18-60 * Current diagnosis of schizophrenia * Significant negative symptoms with few positive symptoms (e.g. hallucinations, delusions) and no evidence of major depression. * Female subjects of childbearing potential must test negative for pregnancy at the time of enrollment...

Countries:United States
Unlock Eligibility Criteria